Nouveau Inc Moves Forward On Dividend To Puration Inc Shareholders Updating Nevada Registration
January 16 2019 - 11:04AM
InvestorsHub NewsWire
Nouveau Inc Moves Forward On Dividend To
Puration Inc
Shareholders Updating Nevada
Registration
Dallas, TX -- January 16, 2019 -- Investorshub NewsWire -- Nouveau Life
Pharmaceuticals, Inc. (dba/Nouveau Inc.) (USOTC:
NOUV) ("NOUV")
and Puration, Inc. (USOTC:
PURA) ("PURA") today announced that NOUV has updated its filings with
the Nevada
Secretary of State bringing
the company current and disclosing the new officers.
Brian Shibley,
the current CEO PURA
has been appointed
as the interim CEO of NOUV.
On October
4, 2018, PURA
sold its cannabis cultivation business to NOUV in exchange for
a $1.2 million convertible note with a
commitment that the note would promptly be converted
into
shares of NOUV and that those converted shares would be distributed
in a stock dividend to the shareholders of PURA.
Brian
Shibley's
appointment as CEO
is anticipated to accelerate the update of NOUV public filings and
in so doing, speed up the anticipated dividend of NOUV shares to
PURA shareholders.
"Shareholders of NOUV and PURA can expect to
see public fling updates this week in addition to the Nevada filing announced
here," said Brian Shibley,
the CEO of both companies. "As I mentioned yesterday, I will make sure through public announcements
that shareholders are kept abreast of the updates on a blow by blow
basis."
$5 Million In Potential 2019
Revenue
Mr. Shibley also reemphasized that the cultivation business acquired by NOUV is
thriving and benefiting from
the recent legalization of hemp farming in the U.S. under the 2018
Farm Act. NOUV plans to plant 100
acres of hemp this spring adding to its existing cultivation operations. The hemp
farming is anticipated to generate up to $5 million in
revenue.
For more information
visit http://www.purationinc.com
Disclaimer/Safe
Harbor:
This news release contains
forward-looking statements within the meaning of the Securities
Litigation Reform Act. The statements reflect the Company's current
views with respect to future events that involve risks and
uncertainties. Among others, these risks include the expectation
that any of the companies mentioned herein will achieve significant
sales, the failure to meet schedule or performance requirements of
the companies' contracts, the companies' liquidity position, the
companies' ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not occur.
These statements have not been evaluated by the Food and Drug
Administration. These products are not intended to diagnose, treat,
cure, or prevent any disease.
Contact:
Puration,
Inc.
Brian
Shibley,
info@aciconglomerated.com
(800) 861-1350
Nouveau Life Pharmaceuti... (PK) (USOTC:NOUV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nouveau Life Pharmaceuti... (PK) (USOTC:NOUV)
Historical Stock Chart
From Apr 2023 to Apr 2024